CMS Posts Preliminary Payment Determination for New Category I CPT Code Covering Use of OGM for Constitutional Genetic Disorders

SAN DIEGO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) offering CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), today announced that Centers for Medicare & Medicaid Services (CMS) posted the preliminary payment determination for the Category I Current Procedural Terminology (CPT®) code for use of OGM in cytogenomic genome-wide analysis to detect structural and copy number variations related to constitutional genetic disorders. According to the preliminary determination, CMS will crosswalk to a previously established proprietary laboratory analyte (PLA) code for OGM, which is priced at $1263.53. Pricing at this level is $363.53 higher than 81228 and $103.53 higher than 81229, comparative codes that apply to use of microarrays and is listed on the clinical lab fee schedule (CLFS) at $900 (81228) and $1160 (81229).